Literature DB >> 9546606

Apparent cleavage of poly(ADP-ribose) polymerase in non-apoptotic mouse LTA cells: an artifact of cross-reactive secondary antibody.

I I Budihardjo1, G G Poirier, S H Kaufmann.   

Abstract

Proteolytic cleavage of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) to fragments of 89 kD and 24 kD is widely observed during apoptotic cell death. In the present study, labelling of a Mr approximately 89000 polypeptide was demonstrated in untreated mouse LTA cells during probing of immunoblots with C-2-10 monoclonal anti-PARP antibody. The source of the labeling was traced to the secondary antibody preparation, which labeled a Mr approximately 89000 polypeptide in murine LTA cells but not in human cells. These observations indicate that assessment of PARP cleavage must be (1) performed with appropriate controls when new cell lines are investigated and (2) carefully interpreted in light of additional biochemical or morphological data demonstrating apoptotic changes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9546606     DOI: 10.1023/a:1006808001462

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  25 in total

1.  Detection of poly(ADP-ribose) polymerase and its apoptosis-specific fragment by a nonisotopic activity-western blot technique.

Authors:  G M Shah; S H Kaufmann; G G Poirier
Journal:  Anal Biochem       Date:  1995-12-10       Impact factor: 3.365

Review 2.  Mammalian cell death proteases: a family of highly conserved aspartate specific cysteine proteases.

Authors:  E S Alnemri
Journal:  J Cell Biochem       Date:  1997-01       Impact factor: 4.429

Review 3.  Protease activation during apoptosis: death by a thousand cuts?

Authors:  S J Martin; D R Green
Journal:  Cell       Date:  1995-08-11       Impact factor: 41.582

4.  Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis.

Authors:  D W Nicholson; A Ali; N A Thornberry; J P Vaillancourt; C K Ding; M Gallant; Y Gareau; P R Griffin; M Labelle; Y A Lazebnik
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

5.  Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells.

Authors:  A M Ibrado; Y Huang; G Fang; L Liu; K Bhalla
Journal:  Cancer Res       Date:  1996-10-15       Impact factor: 12.701

6.  Mch3, a novel human apoptotic cysteine protease highly related to CPP32.

Authors:  T Fernandes-Alnemri; A Takahashi; R Armstrong; J Krebs; L Fritz; K J Tomaselli; L Wang; Z Yu; C M Croce; G Salveson
Journal:  Cancer Res       Date:  1995-12-15       Impact factor: 12.701

7.  Structural and functional analysis of poly(ADP ribose) polymerase: an immunological study.

Authors:  D Lamarre; B Talbot; G de Murcia; C Laplante; Y Leduc; A Mazen; G G Poirier
Journal:  Biochim Biophys Acta       Date:  1988-07-13

Review 8.  ICE/CED3-like proteases as therapeutic targets for the control of inappropriate apoptosis.

Authors:  D W Nicholson
Journal:  Nat Biotechnol       Date:  1996-03       Impact factor: 54.908

9.  Molecular ordering of the cell death pathway. Bcl-2 and Bcl-xL function upstream of the CED-3-like apoptotic proteases.

Authors:  A M Chinnaiyan; K Orth; K O'Rourke; H Duan; G G Poirier; V M Dixit
Journal:  J Biol Chem       Date:  1996-03-01       Impact factor: 5.157

10.  Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis.

Authors:  C A Casiano; S J Martin; D R Green; E M Tan
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

View more
  2 in total

1.  [The apoptosis marker enzyme poly-(ADP-ribose) polymerase (PARP) in systemic lupus erythematosus].

Authors:  I Böhm
Journal:  Z Rheumatol       Date:  2006-10       Impact factor: 1.372

2.  Dominant effects of Δ40p53 on p53 function and melanoma cell fate.

Authors:  Rie Takahashi; Svetomir N Markovic; Heidi J Scrable
Journal:  J Invest Dermatol       Date:  2013-09-13       Impact factor: 8.551

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.